ANGIOTENSIN ll ACETATE

Post-LOE

angiotensin ii

ANDAINTRAVENOUSSOLUTION
Approved
Jun 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
7

Mechanism of Action

release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein coupled-angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.

Pharmacologic Class:

Vasoconstrictor

Clinical Trials (5)

NCT06351150Phase 3Recruiting

Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

Started Jul 2024
NCT00923156Phase 2Completed

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

Started May 2009
123 enrolled
Heart Failure
NCT00237588Phase 4Completed

Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)

Started Dec 2004
25 enrolled
Hypertension
NCT00067990Phase 4Completed

Angiotensin II Blockade for Chronic Allograft Nephropathy

Started Dec 2002
153 enrolled
Kidney DiseaseProteinuria
NCT00320970N/ACompleted

Angiotensin II Antagonism of TGF-Beta 1

Started Aug 2002
36 enrolled
Diabetic NephropathyHypertension